ANAB Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -50.53% compared to AnaptysBio's net margin of --. AnaptysBio's return on equity of -241.25% beat Perspective Therapeutics's return on equity of --.

AnaptysBio has a consensus price target of $37.64, signalling upside risk potential of 110.73%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 602.09%. Given that Perspective Therapeutics has higher upside potential than AnaptysBio, analysts believe Perspective Therapeutics is more attractive than AnaptysBio.

AnaptysBio has a beta of -0.095, which suggesting that the stock is 109.47% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

AnaptysBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

AnaptysBio quarterly revenues are $43.1M, which are larger than Perspective Therapeutics quarterly revenues of --. AnaptysBio's net income of -$21.8M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, AnaptysBio's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio is 5.55x versus 13.27x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Inspire Medical Systems has a net margin of -50.53% compared to AnaptysBio's net margin of 14.69%. AnaptysBio's return on equity of -241.25% beat Inspire Medical Systems's return on equity of 8.4%.

AnaptysBio has a consensus price target of $37.64, signalling upside risk potential of 110.73%. On the other hand Inspire Medical Systems has an analysts' consensus of $230.07 which suggests that it could grow by 53.69%. Given that AnaptysBio has higher upside potential than Inspire Medical Systems, analysts believe AnaptysBio is more attractive than Inspire Medical Systems.

AnaptysBio has a beta of -0.095, which suggesting that the stock is 109.47% less volatile than S&P 500. In comparison Inspire Medical Systems has a beta of 1.390, suggesting its more volatile than the S&P 500 by 38.99%.

AnaptysBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inspire Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio pays -- of its earnings as a dividend. Inspire Medical Systems pays out -- of its earnings as a dividend.

AnaptysBio quarterly revenues are $43.1M, which are smaller than Inspire Medical Systems quarterly revenues of $239.7M. AnaptysBio's net income of -$21.8M is lower than Inspire Medical Systems's net income of $35.2M. Notably, AnaptysBio's price-to-earnings ratio is -- while Inspire Medical Systems's PE ratio is 86.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio is 5.55x versus 5.65x for Inspire Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -50.53% compared to AnaptysBio's net margin of -49.65%. AnaptysBio's return on equity of -241.25% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

AnaptysBio has a consensus price target of $37.64, signalling upside risk potential of 110.73%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 51.84%. Given that AnaptysBio has higher upside potential than NovaBay Pharmaceuticals, analysts believe AnaptysBio is more attractive than NovaBay Pharmaceuticals.

AnaptysBio has a beta of -0.095, which suggesting that the stock is 109.47% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

AnaptysBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

AnaptysBio quarterly revenues are $43.1M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. AnaptysBio's net income of -$21.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, AnaptysBio's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio is 5.55x versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals has a net margin of -50.53% compared to AnaptysBio's net margin of -9.24%. AnaptysBio's return on equity of -241.25% beat Vanda Pharmaceuticals's return on equity of -3.49%.

AnaptysBio has a consensus price target of $37.64, signalling upside risk potential of 110.73%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $12.67 which suggests that it could grow by 190.52%. Given that Vanda Pharmaceuticals has higher upside potential than AnaptysBio, analysts believe Vanda Pharmaceuticals is more attractive than AnaptysBio.

AnaptysBio has a beta of -0.095, which suggesting that the stock is 109.47% less volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.720, suggesting its less volatile than the S&P 500 by 28.044%.

AnaptysBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

AnaptysBio quarterly revenues are $43.1M, which are smaller than Vanda Pharmaceuticals quarterly revenues of $53.2M. AnaptysBio's net income of -$21.8M is lower than Vanda Pharmaceuticals's net income of -$4.9M. Notably, AnaptysBio's price-to-earnings ratio is -- while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio is 5.55x versus 1.28x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.